SLC7A11 and neoplasm: Crucially, we propose the therapeutic paradigm of rational combination therapy, demonstrating that USP43-high neoplasms exhibit enhanced vulnerability to synergistic tumoricidal efficacy when targeted with SLC7A11 inhibitors in concert with platinum-based agents like cisplatin.